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Introduction
Smoke from herbal asthma remedies may cause
the development of emphysema.
Case report
A 79-year-old man was referred to us for possible
lung volume reduction surgery. He was a lifelong
non-smoker but had had mild asthma since the
age of 10. He had never required hospitalization
nor used inhaled bronchodilators until a few
years previously when he had been diagnosed
with COPD. His MRC dyspnoea score was 4.
Spirometry revealed an FEV1 of 0.88L (25% pre-
dicted), an FVC of 4.48 L (94%) predicted with an
FEV1/VC ratio of 24% and no additional improve-
ment with bronchodilators. Lung volumes were
increased; total lung capacity was 117% predicted
and residual volume 156% predicted. Gas transfer
values were reduced; TLcoc of 35% predicted,
Kcoc of 63% predicted. Arterial PaCO2 was
4.0 kPa and PaO2 7.2 kPa. CT thorax showed
diffuse emphysema throughout both lungs, with
bullous changes at both bases (Figure 1).
He reported no occupational exposure to any
pulmonary irritants, nor any exposure to animals
or birds. Further enquiry revealed that from
the age of 12 years, for about 50 years, he had
controlled his asthma by inhaling smoke from a
preparation called Potter’s ‘Asthma Remedy’, the
presumptive cause of his emphysema.
Discussion
This case highlights the need, especially in older
patients, to consider historical medications and
alternative therapies as well as current treatment.
Asthma was described by early civilizations and
treated with herbal smoke inhalation (Ebers
Papyrus 1889). Traditional Chinese medicine
advocated use of herbs, such as Ephedra sinica, con-
taining ephedrine as a bronchodilator. Datura stra-
monium and Lobelia inﬂate, the key constituents of
the Potters ‘Asthma Remedy’ (Saunders M. 2009
Inhalitorium Museum Collection. See http://
www.inhalatorium.com/index.html) used by our
patient, were commonly used in medicinal ciga-
rettes in the United States,
1 and mainland
Europe until recently.
2 Potter’s inhalation
powder continued to be manufactured until 1988
when the UK’s Department of Health refused to
renew the product licence.
Datura stramonium’s principle mechanism
of action when the smoke is inhaled is anti-
cholinergic bronchodilatation, with efﬁcacy
similar to salbutamol via metered dose inhaler,
2
although the duration of action is shorter. Lobelia
inﬂate was introduced as a medication in 1813
and is a plant alkaloid with mixed antagonism
to nicotinic acetyl-choline receptors. Apart from
its principle mechanism of bronchial vasodilata-
tion, it has been used as a nicotine substitute, as
it acts on central dopaminergic systems and for
these reasons was often included in asthma
cigarettes.
1
While asthma and COPD are different diseases
with differing clinical, pathological and immuno-
logical features, they share common processes of
chronic airway remodelling and smooth muscle
proliferation. In approximately 10% of patients,
the speciﬁc features can overlap and are difﬁcult
to distinguish – especially in older people. The
cornerstone for the development of COPD is
mucosal irritation by smoke particles associated
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1with reactive oxygen species, inﬂammatory
cytokines and proteolytic enzymes.
3
It stands to reason that smoking asthma reme-
dies, albeit for therapeutic purposes – would
cause the same thermal injury and smoke particu-
late responses as other noxious inhalations. Even
Herxheimer’s paper, extolling the acute beneﬁcial
effects of D. Stramonium inhalation on the airway,
recalls the concerns of many authors that chronic
airway irritation with these cigarettes could
occur
4 and others have highlighted the potential
risks of contaminants, addiction, carcinogenic par-
ticles and chronic mucosal irritation.
2 Asthmatics
are more susceptible to oxidative stress from
smoking damage than non-smokers and as such
should avoid any form of smoke inhalation if
possible.
We were unable to identify any studies of the
chronic effects of either Lobelia or D. Stramonium
smoke on the airways, nor longitudinal studies
of the prevalence of chronic obstructive pulmon-
ary diseases in patients who have used them. Pre-
sumably this is because they have generally been
viewed (and advertised) as therapies not only for
asthma but for COPD, and have not previously
been thought of as a self-perpetuating cause.
Active asthma has been associated with a 12-fold
increased risk of developing COPD over 20 years
follow-up.
5 While chronic airway inﬂammation
and remodelling might be causal, it is interesting
to speculate that undocumented use of inhala-
tional herbal therapy use might have contributed
to this observation.
In summary, we present the case of a
79-year-old man who had never smoked tobacco,
with severe emphysema, due to chronic inhalation
of smoke from a herbal remedy for previously
mild asthma. The probability of causation
suggests that further epidemiological investi-
gation into the currently unknown size of this
problem is merited. A systematic approach to
survey older asthma and COPD patients about
their exposure may, therefore, be indicated in
order to explore risk factors fully.
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Figure 1
CT thorax showing bilateral basal bullous
emphysema
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